TransIT®-Oligo Transfection Reagent

A high efficiency, low toxicity, transfection reagent optimized for oligonucleotide delivery into a wide range of cell types

To inquire about bulk pricing, please call 888-530-0801
International inquiries please call +1-608-441-2852
Return Policy

Select a Size:

MIR 21640.4 mlMIR 21601 mlMIR 21655 x 1 mlMIR 216610 x 1 ml

Catalog number selected: -


Generate a Quote
  • Unique Formulation – Maximize transfection performance of oligonucleotides into a wide range of cells
  • Low Cellular Toxicity – Maintain cell density and reduce experimental biases
  • High Efficiency Delivery – Achieve high transfection efficiency in cells to ensure experimental success

Oligonucleotides tested:
phosphodiester DNA, phosphothioate DNA (sDNA), phosphothioate RNA (sRNA), 2'OMe RNA, 2'OMe RNA/sDNA Chimerics, Morpholino/DNA duplexes, siRNA and miRNA.

Mirus recommends TriLink BioTechnologies, Inc. for a variety of modified and custom oligonucleotides. Learn more by clicking on their logo below.
trilink logo

Figures and Data

Copy Link Enlarge Image
TransIT-Oligo Reagent Achieves High Transfection Efficiency

TransIT®-Oligo Reagent Achieves High Transfection Efficiency. HeLa cells transfected using TransIT®-Oligo Reagent and Label IT® Cy®3 and Label IT® Fluorescein labeled phosphothioate DNA oligos in complete media for 24 hours.

Copy Link Enlarge Image
TransIT-Oligo Reagent Effectively Transfects a 2'OMe RNA Oligo that Blocks a Cryptic Splice Site

TransIT®-Oligo Reagent Effectively Transfects a 2'OMe RNA Oligo that Blocks a Cryptic Splice Site. The HeLa-Luc 705 reporter cell line (Kang et al. 1998, 37:6235) used in this study contains a luciferase reporter construct that has the ß-globin 705 intron inserted into the luciferase ORF. A mutation present at position 705 of the ß-globin intron activates two cryptic splice sites within the intron that lead to the production of a spliced luciferase mRNA that is disrupted by a small intron with an in-frame stop codon, thus preventing translation of functional luciferase protein. The transfection of a 2'OMe oligonucleotide (TriLink BioTechnologies, Inc.) complementary to the cryptic 705 splice site inhibits splicing at the cryptic splice sites enabling the complete removal of the ß-globin intron and production of a mRNA with a complete, uninterrupted luciferase ORF.

The HeLa-Luc 705 cell line was transfected with increasing amounts of the anti-705 splice site 2'OMe RNA oligo at the indicated final concentrations using the TransIT®-Oligo Transfection Reagent. The cells were harvested 24 hours post-transfection and assayed for luciferase activity. The increase in luciferase activity indicates effective delivery of the anti-705 splice site RNA oligo using the TransIT®-Oligo Reagent.



Storage Conditions:
All Configurations: Store at 4°C

Product Guarantee:
All Configurations: 1 year

Technical Product Literature

Additional Resources

COA Lookup

Download Certificates of Analysis


Excellent technical support, they are very knowledgeable.
He Song Sun
University of Toronto Scarborough - Cell and Molecular Biology